The FDA on December 18, 2024, approved ENSACOVE® for adult patients with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) who have not previously received an ALK-inhibitor. ENSACOVE® is a product of Xcovery Holdings, Inc.
Bottom Ad
Advertisement
Subscribe
